(Reuters) – Bristol Myers Squibb said on Monday it will make an upfront payment of $800 million to SystImmune to co-develop and co-commercialize a type of antibody-drug conjugates (ADC) treatment that precisely targets cancer cells.
(Reporting by Christy Santhosh; Editing by Shinjini Ganguli)
